@Banastas
I am referring to the Phase II trial in the post by @Ellit due for release at the end of next month. There it states it is to be conducted in canines newly diagnosed with lymphoma. No need to go by memory. Another contributor has provided the information.
My point was, I doubt those results will have much effect on market sentiment. All trials build a body of evidence towards the eventual goal, however, some trials are more important than others.
We all know the market wants strong positive results from human trials. If we can chip away at the SP (going up I mean) with little progress reports all the better. However, I do not think the results of this trial will move the market as much as the TA has over the last 2 days.
